Statement issued by the company (Announcement)
Medical breakthroughs are often measured by what is achieved once. At King Faisal Specialist Hospital and Research Centre (KFSH), the more relevant question has become what can be delivered repeatedly, at scale, and within defined time and cost constraints.
Over the past several years, the hospital has moved advanced capabilities from pilot phases into routine clinical use, particularly in oncology, genomics, and minimally invasive surgery, where adoption is assessed not by first cases, but by sustained volumes and operational consistency.
In cell therapy, KFSH has treated more than 200 patients with CAR-T therapy since 2020, initially relying on international manufacturing pathways. By 2025, the program advanced to local production, reducing treatment cost from approximately SAR 1.3 million per case to around SAR 250,000, and shortening production time from about 28 days to less than 14.
In genomics, testing volumes increased from approximately 22,000 to more than 44,000 within two years, reflecting a shift from selective use toward broader integration into diagnosis and treatment planning, supported by computational systems for faster interpretation.
In surgical care, robotic-assisted procedures have moved into repeated use across specialties, contributing in selected cases to shorter hospital stays, sometimes reduced from several days to as little as one day.
Taken together, these patterns point to a model in which innovation is evaluated through measurable indicators such as volume, turnaround time, and cost, rather than isolated milestones.
That shift aligns with discussions at the Milken Institute Global Conference 2026, where KFSH is participating as a Silver Sponsor, alongside global institutions examining how advanced therapies can move from limited availability into scalable models of care.
Within this context, the hospital’s approach offers a practical example of how new technologies can transition into routine clinical delivery through coordinated clinical, manufacturing, and data infrastructure.
Whether such a model can be replicated across different healthcare systems remains an open question; what the KFSH experience provides is a set of operational indicators showing how innovation can move beyond the breakthrough stage into sustained practice.
King Faisal Specialist Hospital &Research Centre has been ranked first in the Middle East and North Africa and 12th globally among the world’s top 250 Academic Medical Centers for 2026 and recognized as the most valuable healthcare brand in the Kingdom and the Middle East according to Brand Finance 2025. It has also been listed by Newsweek among the World’s Best Hospitals 2026, the World’s Best Smart Hospitals 2026, and the World’s Best Specialized Hospitals 2026.
For more information: mediacoverage@kfshrc.edu.sa
AGENCIA EFE S.A.U.,S.M.E. shall not be liable for any information contained in this message and assumes no responsibility towards third parties in relation to its contents, being expressly exempt from any liability that the author may have in relation to the information in question. Agencia EFE reserves the right to distribute the press release on the news wire, or to publish it on EFE Comunica.